What the FDA labels say about taking them together
Cannabidiol and everolimus
Cannabidiol's FDA label of May 29, 2026 names everolimus in its drug interactions section, and everolimus's label names cannabidiol too. The cannabidiol label: “A lower starting dose of orally administered everolimus is recommended.”
Check it at the source: the cannabidiol FDA label on DailyMed (effective May 29, 2026, Jazz Pharmaceuticals, Inc.); the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation).
What does the cannabidiol label say about everolimus?
Cannabidiol label, drug interactionsA lower starting dose of orally administered everolimus is recommended.
Source: FDA drug label (Epidiolex), Jazz Pharmaceuticals, Inc., effective May 29, 2026 (SPL set 8bf27097-4870-43fb-94f0-f3d0871d1eec), via openFDA; the full label on DailyMed
What does the everolimus label say about cannabidiol?
Everolimus label, drug interactionsReduce the dosage as recommended. ( 2.11 , 7.1 ) Cannabidiol oral solution: Reduce the dosage as recommended. ( 2.11 , 7.1 ) Strong CYP3A inducer and P-gp inducer:
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), drug interactionsConsider Zortress dose adjustment ( 5.14 ) Therapeutic drug monitoring and dose reduction for Zortress should be considered when Zortress is coadministered with cannabidiol
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), warnings and precautionsWhen cannabidiol and Zortress are coadministered, closely monitor for an increase in everolimus blood levels and for adverse reactions suggestive of everolimus toxicity.
Source: FDA drug label (Zortress, NDA021560), Novartis Pharmaceuticals Corporation, effective February 12, 2026 (SPL set e082a024-7850-400b-a5c2-2a140612562a), via openFDA
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cannabidiol | Everolimus | |
|---|---|---|
| Labeled for | n/a | Breast cancer, Seizures and epilepsy, Organ transplant rejection |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $26.32 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once